

ATTORNEY DOCKET NUMBER
PHRM-0373

#3

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)
10/019,980INTERNATIONAL APPLICATION NO.
PCT/EP00/06609INTERNATIONAL FILING DATE
03 July 2000PRIORITY DATE CLAIMED
09 July 1999

TITLE OF INVENTION TANKYRASE HOMOLOG PROTEIN (THP), NUCLEIC ACIDS, AND METHODS RELATED TO THE SAME

APPLICANT(S) FOR DO/EO/US Jens BERTHELTSEN, Salvatore TOMA and Antonella ISACCHI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - Transmittal Letter submitting Sequence Listing.
 - Statement to Support Filing and Submission of Sequence Listing.
 - Sequence Listing in written (15 sheets) and computer readable form (1 diskette).
 - Copy of Notification of Missing Requirements.
 - 1 return postcard.

EXPRESS MAIL Mailing Label No. EL 909207245 US
Date of Deposit: 11 April 2002

EL 909207245US

U.S. APPLICATION NO. (if known 37 C.F.R. 1.5) 10/019,980		INTERNATIONAL APPLICATION NO. PCT/EP00/06609		ATTORNEY DOCKET NUMBER PHRM-0373	
17. <u> </u> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1,040.00 International preliminary examination fee (37 CFR 1.482 not paid to USPTO but International Search Report has been prepared by the EPO or JPO.....\$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				<div style="text-align: center; border-bottom: 1px solid black;"> CALCULATIONS PTO USE ONLY </div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <u> </u> 20 <u> X </u> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="text-align: right;">\$130.00</div>	
Claims	Number Filed	Number Extra	Rate		
Total claims	64- 20 =	44	X \$18.00	\$ 792.00	
Independent Claims	5- 3 =	2	x \$84.00	\$ 168.00	
Multiple dependent claims(s) (if applicable)			+ \$280.00	\$ 280.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,370.00	
<u> </u> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				<div style="text-align: right;">\$</div>	
SUBTOTAL =				\$1,370.00	
Processing fee of \$130.00 for furnishing the English translation later than <u> </u> 20 <u> </u> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				<div style="text-align: right;">+ \$</div>	
TOTAL NATIONAL FEE =				\$1,370.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				<div style="text-align: right;">+ \$ 40.00</div>	
TOTAL FEES ENCLOSED =				\$1,410.00	
01/16/2002 LLENDGRA 00000096 10019980 01 FC:154 130.00 OP 01 FC:966 792.00 OP 01 FC:964 168.00 OP 01 FC:968 280.00 OP				<div style="text-align: right;">Amount to be:</div> <div style="text-align: right; border-bottom: 1px solid black;">refunded \$</div> <div style="text-align: right; border-bottom: 1px solid black;">charged \$</div>	
a. <u> X </u> A check in the amount of \$ 1,410.00 to cover the above fee is enclosed. b. <u> </u> Please charge my Deposit Account No. 23-3050 in the amount of \$ <u> </u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <u> X </u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-3050. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Mark DeLuca Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100					
<div style="text-align: right; border-bottom: 1px solid black; margin-bottom: 5px;"> </div> <div style="text-align: right;">SIGNATURE</div>				<div style="text-align: right; border-bottom: 1px solid black; margin-bottom: 5px;">Paul K. Legaard</div> <div style="text-align: right;">NAME</div>	
<div style="text-align: right; border-bottom: 1px solid black; margin-bottom: 5px;">38,534</div> <div style="text-align: right;">REGISTRATION NUMBER</div>					



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/019,980	FIRST NAMED APPLICANT Jens Berthelsen	ATTY. DOCKET NO. PHRM-0373
---	--	-------------------------------

INTERNATIONAL APPLICATION NO. PCT/EP00/06609	
I.A. FILING DATE 07/03/2000	PRIORITY DATE 07/09/1999

Mark DeLuca
Woodcock Washburn
One Liberty Place - 46th Floor
Philadelphia, PA 19103


RECEIVED

APR 01 2002

Woodcock Washburn Kurtz
MacKinnon & MacKinnon LLP

CONFIRMATION NO. 9431

371 FORMALITIES LETTER



OC000000007707372

Date Mailed: 03/27/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Request for Immediate Examination

RECEIVED

APR 01 2002

DOCKET DEPT.
WWKMN

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- Additional claim fees of **\$988** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$1118** for a Large Entity:

- **\$130** Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is **\$988**
 - **\$168** for **2** independent claims over 3.
 - **\$540** for **30** total claims over 20.
 - **\$280** for multiple dependant claims surcharge.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/019,980	PCT/EP00/06609	PHRM-0373

FORM PCT/DO/EO/905 (371 Formalities Notice)

#5

PHRM-0373

Rec'd PCT/PTO 11 APR 2002

IN THE UNITED STATES RECEIVING OFFICE
Before the United States Receiving Office
for the Patent Cooperation Treaty

In re application of:

Jens BERTHELSEN, et al.

U.S. Serial No.: 10/019,980

International Filing Date: 03 July 2000

For: TANKYRASE HOMOLOG PROTEIN (THP), NUCLEIC ACIDS, AND METHODS
RELATED TO THE SAME

Assistant Commissioner for Patents
BOX PCT DO/EO/US
Washington, DC 20231

TRANSMITTAL LETTER SUBMITTING SEQUENCE LISTING

Applicant submits herewith the Sequence Listing in written (15 sheets) and
computer readable form (1 diskette), the contents of which are the same.

The enclosed Sequence Listing does not go beyond the disclosure in the
international application as filed.

Respectfully submitted,



Paul K. Legaard
Registration No. 38,534

/vc

Enc.: 1 Diskette ; 15 sheets sequence listing
Date: 11 April 2002
WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100